Capital Investment Services of America Inc. lowered its position in Danaher Co. (NYSE:DHR) by 0.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 179,523 shares of the conglomerate’s stock after selling 1,165 shares during the quarter. Danaher accounts for 2.6% of Capital Investment Services of America Inc.’s investment portfolio, making the stock its 7th biggest position. Capital Investment Services of America Inc.’s holdings in Danaher were worth $16,663,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently modified their holdings of DHR. Vanguard Group Inc. lifted its stake in shares of Danaher by 1.3% during the second quarter. Vanguard Group Inc. now owns 41,488,407 shares of the conglomerate’s stock worth $3,501,206,000 after purchasing an additional 520,776 shares in the last quarter. BlackRock Inc. lifted its stake in shares of Danaher by 3.2% during the second quarter. BlackRock Inc. now owns 39,201,798 shares of the conglomerate’s stock worth $3,308,239,000 after purchasing an additional 1,233,876 shares in the last quarter. FMR LLC lifted its stake in shares of Danaher by 0.9% during the second quarter. FMR LLC now owns 19,624,350 shares of the conglomerate’s stock worth $1,656,100,000 after purchasing an additional 183,183 shares in the last quarter. Parnassus Investments CA lifted its stake in shares of Danaher by 0.3% during the third quarter. Parnassus Investments CA now owns 9,796,584 shares of the conglomerate’s stock worth $840,351,000 after purchasing an additional 29,381 shares in the last quarter. Finally, Flossbach Von Storch AG lifted its stake in shares of Danaher by 17.2% during the third quarter. Flossbach Von Storch AG now owns 6,776,921 shares of the conglomerate’s stock worth $581,324,000 after purchasing an additional 994,902 shares in the last quarter. Hedge funds and other institutional investors own 76.05% of the company’s stock.

Danaher Co. (NYSE DHR) traded up $3.62 during trading hours on Tuesday, hitting $98.87. The company had a trading volume of 2,886,214 shares, compared to its average volume of 2,382,360. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.00 and a current ratio of 1.43. Danaher Co. has a fifty-two week low of $78.97 and a fifty-two week high of $95.31. The firm has a market capitalization of $67,900.00, a PE ratio of 29.43, a price-to-earnings-growth ratio of 2.07 and a beta of 1.03.

Danaher (NYSE:DHR) last released its quarterly earnings results on Thursday, October 19th. The conglomerate reported $1.00 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.95 by $0.05. Danaher had a return on equity of 11.29% and a net margin of 13.36%. The business had revenue of $4.53 billion for the quarter, compared to analysts’ expectations of $4.47 billion. During the same quarter in the previous year, the firm posted $0.87 earnings per share. The company’s revenue was up 9.6% compared to the same quarter last year. equities research analysts expect that Danaher Co. will post 3.99 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 26th. Investors of record on Friday, December 29th will be paid a $0.14 dividend. This represents a $0.56 annualized dividend and a dividend yield of 0.57%. The ex-dividend date is Thursday, December 28th. Danaher’s dividend payout ratio (DPR) is 16.67%.

A number of research analysts have commented on the company. Cowen restated a “buy” rating and set a $90.00 price objective on shares of Danaher in a research note on Wednesday, October 4th. Zacks Investment Research cut Danaher from a “buy” rating to a “hold” rating in a research note on Tuesday, December 19th. Evercore ISI assumed coverage on Danaher in a research note on Wednesday, January 3rd. They set an “outperform” rating on the stock. Royal Bank of Canada restated a “hold” rating and set a $96.00 price objective on shares of Danaher in a research note on Thursday, January 4th. Finally, Robert W. Baird boosted their price objective on Danaher from $87.00 to $97.00 and gave the stock an “outperform” rating in a research note on Friday, October 20th. One research analyst has rated the stock with a sell rating, six have given a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. Danaher presently has an average rating of “Buy” and a consensus target price of $94.91.

In related news, SVP Daniel Raskas sold 37,870 shares of the business’s stock in a transaction dated Thursday, November 16th. The stock was sold at an average price of $93.33, for a total value of $3,534,407.10. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Donald J. Ehrlich sold 10,578 shares of the business’s stock in a transaction dated Tuesday, October 24th. The stock was sold at an average price of $90.82, for a total value of $960,693.96. Following the completion of the transaction, the director now owns 104,621 shares in the company, valued at approximately $9,501,679.22. The disclosure for this sale can be found here. In the last quarter, insiders sold 273,810 shares of company stock worth $25,218,813. Insiders own 12.20% of the company’s stock.

TRADEMARK VIOLATION WARNING: This report was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The original version of this report can be read at https://www.thecerbatgem.com/2018/01/09/danaher-co-dhr-is-capital-investment-services-of-america-inc-s-7th-largest-position.html.

Danaher Profile

Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR).

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Stock Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related stocks with our FREE daily email newsletter.